The effectiveness of Nirmatrelvir in treating COVID-19 during the Omicron variant surge
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
|
Posted on August 29th, 2022
|
Following the clinical guideline created by the National Institute of Health, Nirmatrelvir is currently being used in a combination with Ritonavir to treat COVID-19. Nirmatrelavir inhibits the essential protein 3CLpro that is necessary for viral replication. Due to the Omicron variant surge, antiviral resistance might nullify the medication’s effectiveness. A recent study published in the New England Journal of Medicine had investigated this concern.
The retrospective cohort study included 109,254 participants older than 40 years, had been diagnosed with COVID-19 in an outpatient setting, and had a high probability of experiencing severe disease. 3,902 of them received Nirmatrelavir, and among those who were 65 years of age or older, the medication helps reduce the hazard of hospitalization by one-quarter and death by one-fifth. The antiviral is less effective in patients 40 to 64 years of age; the rate of hospitalization and death is similar between the two groups.
Due to the low efficacy in younger adults, other studies need to be conducted to confirm this observation. If the association is confirmed, appropriate adjustments must be made to the clinical guideline. Additional studies will also be beneficial to elucidate any antiviral resistance activity.
The retrospective cohort study included 109,254 participants older than 40 years, had been diagnosed with COVID-19 in an outpatient setting, and had a high probability of experiencing severe disease. 3,902 of them received Nirmatrelavir, and among those who were 65 years of age or older, the medication helps reduce the hazard of hospitalization by one-quarter and death by one-fifth. The antiviral is less effective in patients 40 to 64 years of age; the rate of hospitalization and death is similar between the two groups.
Due to the low efficacy in younger adults, other studies need to be conducted to confirm this observation. If the association is confirmed, appropriate adjustments must be made to the clinical guideline. Additional studies will also be beneficial to elucidate any antiviral resistance activity.